anaplastic lymphona kinase-positive non-small cell lung cancer

source: pixabay.com

Real-World Data on Brigatinib as a Treatment for ALK+ Non-Small Cell Lung Cancer

Post author:Kendall Mason
Post published:June 1, 2021
Post category:Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Brigatinib has been approved for the treatment of ALK+ metastatic non-small cell lung cancer (NSCLC), as well as ALK+ NSCLC patients who have received prior treatment with crizotinib. While it…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More